Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

Nano milling is a vital technique for developing fine particle-sized drug formulations and improving bioavailability of water-soluble APIs.

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to ...

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Coave has raised €32m ($33m) in a Series A financing round for advancing its Advanced Vectors-Ligand Conjugates (ALIGATER) platform.